Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Our products are used to help care for critically and chronically ill patients. The people of Fresenius Kabi are driven by a common purpose: to put lifesaving medicines and technologies in the hands of people who care for patients, and to find answers to the challenges they face.
For more information about Fresenius Kabi, click here.
Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs. NAROPIN may be associated with adverse reactions which are characteristic of those associated with other amide-type local anesthetics.1 In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information.
1. NAROPIN Prescribing Information Data on file.
NAROPIN is indicated for the production of local or regional anesthesia for surgery and acute pain management.
NAROPIN and logo are registered trademarks of Fresenius Kabi USA, LLC. ©2015, Fresenius Kabi USA, LLC. All Rights Reserved.